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The aim of this study was to determine the effect of dietary quercetin supplementation on blood lipids and TNF-a levels according to the apoE
genotype in apoE3 and apoE4 targeted gene replacement mice. In a two-factorial design female apoE3 and apoE4 mice were fed semi-synthetic
diets without (controls) and with quercetin (2mg/g diet) for 6 weeks. Feeding the quercetin-supplemented diets significantly increased plasma
levels of quercetin and isorhamnetin both in apoE3 and apoE4 mice. There was no significant effect of apoE genotype on plasma quercetin
levels. ApoE3 and apoE4 transgenic mice exhibited similar plasma levels of apoE and cholesterol which were not significantly affected by dietary
quercetin supplementation. In mice receiving the basal diet without quercetin supplementation, levels of TNF-a in whole blood stimulated ex vivo
with lipopolysaccharide were higher in apoE3 as compared to apoE4 transgenic mice. Dietary quercetin significantly lowered levels of TNF-a by
44% in apoE3 mice relative to apoE3 mice receiving the unsupplemented diets. In apoE4 mice a moderate (20%) but not significant decrease in
TNF-a levels in response to the quercetin supplementation was evident. Following quercetin supplementation TNF-a levels were similar between
apoE3 and apoE4 transgenic mice. Current findings indicate that apoE3 mice are more responsive to the TNF-a lowering properties of dietary
quercetin supplementation as compared to apoE4 animals.
ApoE polymorphism: Quercetin: TNF-a
Flavonoids are a large group of secondary plant metabolites
with more than 6000 different compounds described
to date. One important flavonoid subclass, the flavonols,
and their major representative quercetin are ubiquitously
distributed in plant foods and thus ingested in appre-
ciable amounts with the daily diet. Particularly rich
sources of quercetin are onions, apples and tea(1,2). Epide-
miological studies have revealed that the Mediterranean
diet, which is particularly abundant in flavonoid-rich
foods, correlates with increased longevity and a decreased
incidence of CHD(3,4). Dietary quercetin supplementation
has recently been shown to lower platelet aggregation(5)
and blood pressure in man(6). Furthermore, numerous cell
culture studies indicate a potent antinflammatory activity
of quercetin(7–11).
ApoE is a polymorphic multifunctional protein with three
common isoforms in man (E2, E3 and E4). ApoE3 is the
wild-type and most common isoform, while apoE4 carriers
account for about 25% of the Caucasian population(12). Pre-
sence of the apoE4 allele is associated with a 40–50%
higher risk of CVD(13) and apoE4 is the major known genetic
risk factor for maturity-onset Alzheimer’s disease(14,15).
Although apoE4 is strongly linked to both diseases, the mol-
ecular basis of these associations remains uncertain. Tradition-
ally, the differences in disease risk have been attributed to the
increased LDL-cholesterol (about 8%) observed in apoE4
carriers, but it is becoming increasingly evident that this
alone cannot explain the disease differential(16). ApoE is not
only synthesised by the liver, but also in the brain and by
resident macrophages(17) in the atherosclerotic wall, where it
exerts atheroprotective actions, independent of its role in
lipid metabolism(18).
Our group has previously shown that the apoE genotype
significantly affects the cellular inflammatory response in
stably transfected murine macrophages. In apoE4 v. apoE3
macrophages higher levels of proinflammatory cytokines
including TNF-a were evident following stimulation with
lipopolysaccharide(19). However, these findings refer to an
in vitro situation and it is not known if the apoE genotype
also affects biomarkers of inflammation in vivo. Furthermore,
to the best of our knowledge no studies have examined the
interaction between dietary flavonoids, apoE genotype and
biomarkers of inflammation in vivo which is the aim of the
present study.
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Experimental methods
Mice and diets
Female homozygous apoE3 and apoE4 targeted replacement
mice (6–8 weeks old) ‘humanized’ for the apoE gene were
purchased from Taconic Europe (Ry, Denmark). Generation
of the apoE3 and apoE4 models was recently described(20).
Mice of both genotypes were assigned into one of two possible
dietary groups (n 8), and were kept in macrolon cages at
21–258C, with a 12 h day–night cycle.
The diets and water were provided ad libitum for 6 weeks
and live weight recorded weekly. Mice were kept according
to the German Regulations of Animal Welfare with per-
mission of the responsible authority. The semi-synthetic diet,
based on maize starch (15%), casein (20%), sucrose (33%)
and butter fat (21%) (so-called ‘Western diet’), was purchased
from Ssniff Special Diets (Soest, Germany). Diets were sup-
plemented with 0 or 2mg quercetin/g diet, as dihydrate
($98% purity; Roth, Karlsruhe, Germany).
Sample collection and tissue preparation
At the end of the dietary intervention period, mice were anaes-
thetised and decapitated. The blood was collected in EDTA-
tubes, and the plasma was separated by centrifugation
(8000 g, 4min, 48C) and stored at 2808C. An aliquot of
EDTA-blood was diluted 1:10 with RPMI 1640 medium (sup-
plemented with 10% fetal calf serum and 100U/ml penicillin
and 100mg/ml streptomycin; all from PAA, Coelbe, Germany)
and stimulated with 100 ng/ml lipopolysaccharide (from
Salmonella enteritidis; Sigma, Deisenhofen, Germany) for
24 h as adapted from Miles et al. (21). Accordingly, the super-
natants were collected, centrifuged and cell-free samples were
stored for further analysis at 2808C. Mice were genotyped
according to the method of Zivelin et al. (22).
Cholesterol levels and apoE concentrations
Plasma total cholesterol and apoE concentrations were deter-
mined on an ILAB 600 automatic analyser (Instrumentation
Laboratories UK Ltd, Warrington, UK), using commercially
available spectrophotometric kits (TC, Instrumentation Lab-
oratories Ltd) and turbimetric immunoassay kits (Apolipo-
protein E-HAWako; Alpha Laboratories Ltd, Eastleigh, UK).
TNF-a levels
TNF-a concentrations in the supernatants of whole-blood cul-
ture were determined by the mouse TNFa DuoSet ELISA
development kit (R&D Systems, Wiesbaden, Germany).
Quercetin analysis
Analysis of plasma quercetin and its methylated derivative
isorhamnetin (30-O-methyl-quercetin) was performed by
HPLC with fluorescence detection after treatment with a
b-glucuronidase–sulphatase mix as previously described(23).
Statistical analysis
Statistical analysis was performed using SPSS version 13.0
(SPSS, Munich, Germany). Data were analysed for normality of
distribution (Kolmogorow–Smirnov and Shapiro–Wilk tests)
and equality of variance (Levene test) prior to two-way
ANOVA, which was performed to test the independent effects
of apoE genotype (apoE3 and apoE4), dietary quercetin levels
(0 or 2mg/g diet) and their interactions on the outcomes of inter-
est.A t testwas used to comparemeans of quercetin-fedmicewith
their control genotype. Data are expressed as means with their
standard errors and significance was accepted at P,0·05.
Results
Mice carrying the apoE3 and apoE4 genotype did not differ in
live weight gain over the 6-week experimental period. Further-
more, there was no significant effect of dietary quercetin
supplementation on final body weight in either the apoE3 or
apoE4 transgenic mice (Table 1).
Feeding the quercetin-supplemented diets significantly
increased plasma levels of quercetin and isorhamnetin both
in apoE3 and apoE4 mice to a similar extent. In mice fed
the control diet quercetin was detectable in low concentrations
whereas its metabolite isorhamnetin could only be determined
in traces. There was no significant effect of apoE genotype on
plasma quercetin and isorhamnetin levels (Table 1).
Table 1 shows mean values of plasma apoE and total choles-
terol according to apoE genotype and dietary quercetin sup-
plementation. ApoE3 and apoE4 transgenic mice exhibited
similar plasma levels of both apoE and cholesterol which were
not significantly affected by dietary quercetin. In mice receiving
the basal diet without quercetin supplementation, levels of
TNF-a in whole-blood supernatants after lipopolysaccharide
stimulation were higher in apoE3 as compared to apoE4 trans-
genic mice. Dietary quercetin significantly lowered levels of
TNF-a by 44% in apoE3 mice (P¼0·0015). In apoE4 mice
only a moderate decrease in TNF-a (20%) due to dietary querce-
tin was evident. Following quercetin supplementation TNF-a
levels were similar between apoE3 and apoE4 transgenic mice.
Discussion
Most studies in the literature reporting anti-inflammatory activi-
ties of quercetin were conducted in vitro using quercetin concen-
trations in the cell culture medium of 1–50mmol/l(8,9). In the
present study plasma levels of quercetin of 3·0–3·3mmol/l were
measured. Interestingly, this concentration was sufficient to
induce a significant decrease in TNF-a levels after ex vivo stimu-
lation of whole blood with lipopolysaccharide in apoE3 trans-
genic mice. The dietary quercetin level used in the present
mouse study was set to be 2mg/g diet, which refers to a quercetin
concentration of approximately 400mg/kg body weight. This is
many times higher than quercetin concentrations which can be
normally achieved due to a flavonoid-rich diet in man(24). How-
ever, it needs to be taken into account that quercetin is also avail-
able in a purified form and commercially available quercetin
supplements often contain quercetin concentration in a range
between 500 and 1000mg/capsule(25).
In the present study a targeted gene replacement model was
used to study interactions between apoE genotype and dietary
ApoE genotype, quercetin and TNF-a levels 1441
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quercetin. It is well documented that human apoE4 carriers exhi-
bit lower levels of the apoE isoprotein as compared to man carry-
ing the E3 allele(26). Thus in man it is generally difficult to
differentiate between genotype effects and effects which may
be related to differences in the circulatory levels of the apoE iso-
protein. Since our targeted gene replacement mice exhibited
almost identical amounts of plasma levels of apoE3 and E4,
respectively, potential differences in blood lipids and biomarkers
of inflammation in the presentmouse studyare therefore related to
the apoE3 and E4 isoprotein per se.
Human studies investigating the impact of apoE genotype on
plasma lipid levels have reported mixed findings, with 5–10%
higher total- and LDL-cholesterol levels typically evident in E4
carriers(27,28), an effect which has been attributed to a number
of mechanisms including increased dietary cholesterol absorp-
tion, decreased hepatic LDL receptor-mediated uptake and an
increase in the production rate of LDL from its precursor
VLDL. ApoE3 and apoE4 transgenic mice exhibited similar
plasma levels of apoE and cholesterol which were not signifi-
cantly affected by dietary quercetin supplementation. Cholesterol
homeostasis and LDL receptor activity may also be affected by
quercetin(29,30). However, in vivo effects of quercetin supplemen-
tation on human plasma lipid profile are inconsistent as well. No
changes in plasma lipids were observed after quercetin sup-
plementation in healthy subjects(31,32) whereas markedly lower
blood lipids were found when quercetin (as grape powder/grape
juice) was given to pre- and postmenopausal women(33) and to
haemodialytic and healthy subjects(34).
An important observation of the present study is that, although
the differences did not reach statistical significance, apoE4 mice
receiving the quercetin-free basal diet had 26% lower levels of
TNF-a as compared to apoE3 mice. However, the mouse data
are in contradiction to our data in murine RAW264.7 macro-
phages where elevated levels of TNF-a were evident in E4 v.
E3 macrophages(19). Thus cell culture data regarding apoE geno-
type and inflammation may not be directly extrapolated to an
in vivo situation. Furthermore, it needs to be taken into account
that apoE produced by macrophages contributes only to 20% of
the apoE produced in the human body whereas 80% of apoE is
produced in the liver. In accordance with the present TNF-a
data we found also higher levels of C-reactive protein(20), another
biomarker of inflammation, in apoE3 as compared to apoE4
transgenic mice.
Another finding of the present study is that dietary quer-
cetin significantly decreased TNF-a levels in ex vivo-stimu-
lated whole-blood samples of apoE3 but not apoE4
transgenic mice. Following quercetin supplementation in
mice, TNF-a levels in apoE3 were lower than those in
apoE4. Thus, based on the present findings, it seems likely
that human apoE3 carriers may be more responsive towards
a dietary intervention with flavonoids. Again, the present
finding is in accordance with human data where supplemen-
tation with a-linolenic acid had a stronger effect on bio-
markers of inflammation in apoE3 v. apoE4 carriers(35).
Therefore, the apoE genotype may in part explain the
large heterogeneity of studies regarding potential health
effects of flavonoids in man where cohorts are not genotyped
for apoE polymorphisms.
The underlying molecular and cellular mechanisms by
which dietary quercetin has resulted in a decrease of secreted
TNF-a may be related to its ability to inhibit the NF-kB-
dependent signal transduction cascades as reported earlier(8).
Further studies are warranted to test the hypothesis whether
NF-kB signalling in vivo is different in apoE3 v. apoE4 mice.
The present study reports, for the first time, that dietary
quercetin differentially affects TNF-a levels in E3 and E4 tar-
geted replacement mice. However, the study also has some
limitations. First, the concentration of quercetin used in the
present study was rather high; thus dose-dependent studies
are warranted. Second, whole blood was stimulated with lipo-
polysaccharide to induce TNF-a secretion thus the inflamma-
tory potential rather than the baseline level of circulatory
TNF-a was determined. The model of ex vivo stimulation of
whole blood has been previously used to evaluate the anti-
inflammatory potential of dietary phenolics(21). Finally, the
duration of the experiment was set to be 6 weeks. Therefore
it would be interesting to test the hypothesis whether chronic
feeding with lower doses of quercetin over a longer period of
time would affect TNF-a and other inflammatory cytokines in
relation to apoE genotype. Furthermore, human studies are
warranted to study interactions between dietary flavonoids,
apoE genotype and biomarkers of chronic inflammation.
Table 1. Effect of apoE genotype and dietary quercetin on final body weight, plasma levels of quercetin, blood lipids and
TNF-a levels in apoE3 and apoE4 targeted gene replacement mice‡
(Mean values with their standard errors)
ApoE3 genotype ApoE4 genotype
Control diet Quercetin diet Control diet Quercetin diet
Mean SEM Mean SEM Mean SEM Mean SEM
Initial body weight (g) 18·6 0·54 18·2 0·54 17·8 0·40 17·8 0·34
Final body weight (g) 26·5 2·00 23·6 0·65 24·3 1·45 23·6 0·65
Quercetin (mmol/l plasma) (n 5) 0·421 0·08 3·32*** 0·38 0·333 0·02 2·99†† 0·49
Isorhamnetin (mmol/l plasma) (n 5) 0·001 0·00 4·86** 0·65 0·048 0·01 4·69†† 1·00
Cholesterol (mmol/l plasma) (n 5) 2·96 0·28 3·48 0·10 3·24 0·29 3·41 0·29
ApoE (mg/ml plasma) (n 5) 36·3 3·05 37·6 2·36 34·2 1·82 39·4 3·57
TNF-a (pg/ml blood) (n 8) 44·5 3·06 26·2** 3·13 32·8 5·98 26·5 1·68
Mean values were significantly different from those of the apoE3 control group (t test): **P,0·01, ***P,0·001.
Mean values were significantly different from those of the apoE4 control group (t test): ††P,0·01.
‡ For details of procedures, see Experimental methods. ApoE3 and ApoE4 targeted gene replacement mice were fed a diet without (control;
0mg/g diet) or supplemented (quercetin diet; 2mg/g diet) with quercetin for 6 weeks. Using two-way ANOVA, significant quercetin effects
were observed for plasma quercetin (P,0·001), isorhamnetin (P,0·001) and TNF-a (P,0·01).
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